DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT01661881
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Pilot Study for Young Women's Intervention
- Conditions
- Breast Cancer
- Interventions
- Behavioral: YWIBehavioral: Physical Activity
- First Posted Date
- 2012-07-23
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 93
- Registration Number
- NCT01647594
- Locations
- 🇺🇸
Texas Oncology Cancer Center, Houston, Texas, United States
🇺🇸Eastern Maine Medical Center, Brewer, Maine, United States
🇺🇸Lowell General Hospital, Lowell, Massachusetts, United States
Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Behavioral: Young Women's Intervention (YWI)Behavioral: Physical Activity Intervention (PAI)
- First Posted Date
- 2012-07-23
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 467
- Registration Number
- NCT01647607
- Locations
- 🇺🇸
Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Presence Resurrection Medical Center, Chicago, Illinois, United States
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
- Conditions
- Breast CancerOvarian Cancer
- Interventions
- Drug: BYL719 and OlaparibDrug: BKM120 and Olaparib
- First Posted Date
- 2012-06-20
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 118
- Registration Number
- NCT01623349
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 63
- Registration Number
- NCT01614821
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
- Conditions
- Pancreatic Cancer, Metastatic
- Interventions
- Drug: Gemcitabine, Erlotinib, OSI-906
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT01600807
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma
- Conditions
- Squamous Cell Carcinoma of the Oropharynx
- Interventions
- Radiation: Stereotactic Body Radiotherapy
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT01586182
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
XL-184+Abiraterone in Post-Chemo CRPC
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT01574937
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
- Conditions
- Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
- Interventions
- Drug: SC-PEG
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 240
- Registration Number
- NCT01574274
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy
- Conditions
- Breast Cancer
- Interventions
- Other: MRI
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT01568346
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Faulkner Hospital, Boston, Massachusetts, United States